CTOs on the Move

Enara Health

www.enarahealth.com

 
Enara Health is building a data-driven platform and network to scale obesity treatment. Based in San Mateo, Calif., and operating since March 2015, Enara Health offers unique hybrid digital and in-person weight loss programs based on precision medicine. By combining mobile technology with health care visits and providing patients with personalized physician-driven medical weight loss programs, Enara Health routinely helps patients lose—and keep off—more than 15% of their baseline weight, which is far greater than the results seen with other m-health interventions.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enarahealth.com
  • 3050 South Delaware Street Suite 130
    San Mateo, CA USA 94403
  • Phone: 650.319.8654

Executives

Name Title Contact Details
Felipe Baytelman
Chief Technology Officer Profile

Similar Companies

IARP Headquarters

IARP Headquarters is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MD Business Solutions

MD Business Solutions is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inspyr Therapeutics

Inspyr Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.

Lindora

Lindora is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.